Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 3, 2012, Pages 222-230

  Lee, Dong U ^a   Huang, Wenhu ^a   Rittenhouse, Kay D ^a   Jessen, Bart ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; GENOMIC DNA; PF 655; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BASE MISPAIRING; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA CELL; DNA SEQUENCE; EYE DISEASE; GENE EXPRESSION; GENE REPRESSION; GENE RTP801; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RABBIT; RETINA; RNA GENE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SPECIES COMPARISON;

ANIMALS; CELL LINE, TRANSFORMED; CORNEA; EYE DISEASES; GENE EXPRESSION; GENE SILENCING; GENETIC THERAPY; HEK293 CELLS; HUMANS; RABBITS; RETINA; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84862173320     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0116     Document Type: Article

References (35)

1. Lares, M.R., Rossi, J.J., and Ouellet, D.L. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28:570-579, 2010.
2. Bumcrot, D., Manoharan, M., Koteliansky, V., and Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2:711-719, 2006. (Pubitemid 44764213)
3. Campochiaro, P.A. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 13:559-562, 2006.
4. Hassan, A. Potential applications of RNA interference-based therapeutics in the treatment of cardiovascular disease. Recent Pat. Cardiovasc. Drug Discov. 1:141-149, 2006.
5. Khoury, M., Jorgensen, C., and Apparailly, F. RNAi in arthritis: prospects of a future antisense therapy in inflammation. Curr. Opin. Mol. Ther. 9:483-489, 2007. (Pubitemid 47577405)
6. Emerson, M.V., and Lauer, A.K. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs. 21:245-257, 2007. (Pubitemid 47104980)
7. Novack, G.D. Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu. Rev. Pharmacol. Toxicol. 48:61-78, 2008. (Pubitemid 351738149)
8. Rechtman, E., Harris, A., Garzozi, H.J., and Ciulla, T.A. Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clin. Ophthalmol. 1:383-391, 2007.
9. Barakat, M.R., and Kaiser, P.K. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs. 18:637-646, 2009.
10. Campa, C., and Harding, S.P. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr. Drug Targets. 12:173-181, 2011.
11. Ellisen, L.W., Ramsayer, K.D., Johannessen, C.M., Yang, A., Beppu, H., Minda, K., Oliner, J.D., McKeon, F., and Haber, D.A. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol. Cell. 10:995-1005, 2002. (Pubitemid 35453821)
12. Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., Kalinski, H., Kamer, I., Rozen, A., Mor, O., Keshet, E., Leshkowitz, D., Einat, P., Skaliter, R., and Feinstein, E. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22:2283-2293, 2002. (Pubitemid 34224633)
13. Wang, Z., Malone, M.H., Thomenius, M.J., Zhong, F., Xu, F., and Distelhorst, C.W. Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J. Biol. Chem. 278:27053-27058, 2003. (Pubitemid 36876859)
14. Brugarolas, J., Lei, K., Hurley, R.L., Manning, B.D., Reiling, J.H., Hafen, E., Witters, L.A., Ellisen, L.W., and Kaelin Jr., WG. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18:2893-2904, 2004. (Pubitemid 39602308)
15. Frost, R.A., Huber, D., Pruznak, A., and Lang, C.H. Regulation of REDD1 by insulin-like growth factor-I in skeletal muscle and myotubes. J. Cell Biochem. 108:1192-1202, 2009.
16. Malagelada, C., Lopez-Toledano, M.A., Willett, R.T., Jin, Z.H., Shelanski, M.L., and Greene, L.A. RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J. Neurosci. 31:3186-3196, 2011.
17. Brafman, A., Mett, I., Shafir, M., Gottlieb, H., Damari, G., Gozlan-Kelner, S., Vishnevskia-Dai, V., Skaliter, R., Einat, P., Faerman, A., Feinstein, E., and Shoshani, T. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest. Ophthalmol. Vis. Sci. 45:3796-3805, 2004. (Pubitemid 39298599)
18. Jin, H.O., An, S., Lee, H.C., Woo, S.H., Seo, S.K., Choe, T.B., Yoo, D.H., Lee, S.B., Um, H.D., Lee, S.J., Park, M.J., Kim, J.I., Hong, S.I., Rhee, C.H., and Park, I.C. Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal. 19:1393-1403, 2007. (Pubitemid 46818907)
19. Schwarzer, R., Tondera, D., Arnold, W., Giese, K., Klippel, A., and Kaufmann, J. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene. 24:1138-1149, 2005. (Pubitemid 40313916)
20. Penha, F.M., Rodrigues, E.B., Maia, M., Dib, E., Fiod Costa, E., Furlani, B.A., Nunes Moraes Filho, M., Dreyfuss, J.L., Bottos, J., and Farah, M.E. Retinal and ocular toxicity in ocular application of drugs and chemicals - part I: animal models and toxicity assays. Ophthalmic Res. 44:82-104, 2010.
21. Ng, E.W., Joo, M.J., Au Eong, K.G., Green, W.R., and O'Brien, T.P. Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit. Curr. Eye Res. 27:387-393, 2003. (Pubitemid 38019205)
22. Spence, S. The Dutch-Belted rabbit: an alternative breed for developmental toxicity testing. Birth Defects Res. B Dev. Reprod. Toxicol. 68:439-448, 2003. (Pubitemid 38222020)
23. Fandrey, J., Frede, S., Ehleben, W., Porwol, T., Acker, H., and Jelkmann, W. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int. 51:492-496, 1997. (Pubitemid 27088165)
24. Kenworthy, R., Lambert, D., Yang, F., Wang, N., Chen, Z., Zhu, H., Zhu, F., Liu, C., Li, K., and Tang, H. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res. 37:6587-6599, 2009.
25. Murakami, T., Hasegawa, K., and Yoshinaga, M. Rapid induction of REDD1 expression by endurance exercise in rat skeletal muscle. Biochem. Biophys. Res. Commun. 405:615-619, 2011.
26. Amarzguioui, M., Holen, T., Babaie, E., and Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31:589-595, 2003. (Pubitemid 36175948)
27. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C., and Liang, Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33:1671-1677, 2005. (Pubitemid 41418395)
28. Schwarz, D.S., Ding, H., Kennington, L., Moore, J.T., Schelter, J., Burchard, J., Linsley, P.S., Aronin, N., Xu, Z., and Zamore, P.D. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2:e140, 2006.
29. Marques, J.T., and Williams, B.R. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 23:1399-1405, 2005. (Pubitemid 41679392)
30. Lacaze, P., Raza, S., Sing, G., Page, D., Forster, T., Storm, P., Craigon, M., Awad, T., Ghazal, P., and Freeman, T.C. Combined genome-wide expression profiling and targeted RNA interference in primary mouse macrophages reveals perturbation of transcriptional networks associated with interferon signalling. BMC Genomics. 10:372, 2009.
31. Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., and MacLachlan, I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19:991-999, 2008.
32. Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K., and MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23:457-462, 2005. (Pubitemid 41724921)
33. Sioud, M. Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci. 13:4379-4392, 2008. (Pubitemid 351599690)
34. Williams, S.J., Graepel, G.J., and Kennedy, G.L. Evaluation of ocular irritancy potential: intralaboratory variability and effect of dosage volume. Toxicol. Lett. 12:235-241, 1982. (Pubitemid 13226404)
35. Zayit-Soudry, S., Zemel, E., Loewenstein, A., and Perlman, I. Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina. 30:671-681, 2010.